First CyberKnife(R) System in Clinical Use in Czech Republic

Major Czech Academic Center Expands Care to Offer Radiosurgery

SUNNYVALE, California, October 14, 2010 - Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of
radiosurgery, today announced that the first CyberKnife Robotic Radiosurgery
System in Czech Republic is now treating cancer patients at the University
Hospital of Ostrava (UHO) Clinic of Oncology.

The renowned academic center has created a state-of-the-art oncology
department with the addition of the CyberKnife System, which is housed in a
new dedicated building. With this acquisition, the UHO is now able to
significantly expand its therapeutic options by delivering high doses of
radiation very precisely in only a few sessions. Their clinical program aims
at treating mainly extracranial indications including lung, liver and
prostate.

"With the addition of the CyberKnife System to our Radiation Oncology
department, we are now able to use full body radiosurgery to target tumors
that cannot be easily treated with traditional surgical techniques because of
their location, number, size, shape or proximity to vital tissues or organs,
or because of the age or health of the patient," said David Feltl, M.D.,
Ph.D., MBA, Head of the Oncology Clinic at the UHO. "The intelligent robotics
enables us to deliver radiation doses that conform closely to the shape of
the tumor. This allows for precise targeting of a tumor, while at the same
time minimizes damage to surrounding healthy tissue."

"We are very pleased to see the benefits of whole body radiosurgery
expand into Czech Republic," said Vittorio Puppo, General Manager, Accuray
EIMEA (Europe, India, Middle East and Africa). "This new installation paves
the way for greater patient access to CyberKnife radiosurgery, thereby
providing an additional treatment option to patients who may not have had
other options until now."

About Ostrava University Hospital's Oncology Clinic

Opened in October 1950, the Oncology Centre of UHO is the first Czech
University hospital accredited by the Joint Commission International (JCI).
It ranks among the top facilities in Eastern and Central Europe and
guarantees patients from a wide region state-of-the-art treatment adhering to
world standards. Additionally, it is a part of a network of thirteen
specialized oncology centres in the Czech Republic and is the largest
oncology department in the Moravian-Silesian Region. The hospital is also the
Czech leader in image-guided radiation therapy (IGRT) and has extensive head
and neck and prostate programs. The center uses the latest technologies,
including two linear accelerators with highly energetic photons and
accelerated electrons, virtual simulator, brachytherapy with high dose input
and features teams of top experts. Approximately 4,500 adult patients with
all types of malignant tumors are treated with non surgical methods each year
at UHO. For more information, please visit cyberknife.fno.cz/en

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body
stabilization frames.

About Accuray

Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to deliver more than 100,000
treatments worldwide and more than 206 systems have been installed in leading
hospitals in the Americas, Europe and Asia. For more information, please
visit www.accuray.com.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve
risks and uncertainties, including uncertainties associated with the medical
device industry. Except for the historical information contained herein, the
matters set forth in this press release, including statements relating to
clinical applications, clinical acceptance, clinical benefits, clinical
publications, and clinical results are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements speak only as of the date the
statements are made and are based on information available at the time those
statements are made and/or management's good faith belief as of that time
with respect to future events. You should not put undue reliance on any
forward-looking statements. Important factors that could cause actual
performance and results to differ materially from the forward-looking
statements we make include: market acceptance of products; competing
products, the combination of our products with complementary technology; and
other risks detailed from time to time under the heading "Risk Factors" in
our report on Form 10-K for the 2010 fiscal year which has been filed with
the Securities and Exchange Commission on August 31, 2010. The Company's
actual results of operations may differ significantly from those contemplated
by such forward-looking statements as a result of these and other factors. We
assume no obligation to update forward-looking statements to reflect actual
performance or results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent required by
applicable securities laws.

Sancie Nakarat, Manager, EU Marketing, +33-0-6-81-36-84-34, snakarat at accuray.com, or Stephanie Tomei, +1-408-789-4234, stomei at accuray.com, both of Accuray Incorporated